CEO
Medicines Development for Global Health
Mark Sullivan is Founder and CEO of Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company dedicated to addressing health inequity through developing and delivering new medicines and vaccines for diseases endemic in low and middle income countries. Before forming MDGH in 2005, Mark was a clinical program head at GSK (London) and AD, Clinical at Gilead Sciences, Inc (California). MDGH was the first not for profit company to achieve FDA approval of a new chemical entity: moxidectin, a second generation macrocyclic lactone, was approved for the treatment of onchocerciasis in June 2018 and is now being developed for 4 other neglected tropical diseases. Mark is a clinical research expert and project leader.
Mark’s honors/awards include: Honorary Professor, University of New South Wales; 2019 Victorian Australian of the Year; Fast Company Global 33rd Most Creative Person, 2019; Ernst and Young, Australian Entrepreneur of the Year (Social Category), 2019.
Disclosure information not submitted.
Thursday, January 13, 2022
11:15 AM – 12:15 PM ET
.png)